Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Gross Margin (2021 - 2025)

Historic Gross Margin for BridgeBio Pharma (BBIO) over the last 6 years, with Q3 2025 value amounting to 94.56%.

  • BridgeBio Pharma's Gross Margin rose 164500.0% to 94.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 95.78%, marking a year-over-year decrease of 31200.0%. This contributed to the annual value of 98.25% for FY2024, which is 245400.0% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Gross Margin of 94.56% as of Q3 2025, which was up 164500.0% from 96.7% recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Gross Margin ranged from a high of 286.87% in Q4 2021 and a low of 118.64% during Q3 2022
  • In the last 5 years, BridgeBio Pharma's Gross Margin had a median value of 78.11% in 2024 and averaged 79.54%.
  • Its Gross Margin has fluctuated over the past 5 years, first tumbled by -2214700bps in 2022, then surged by 2040200bps in 2023.
  • Quarter analysis of 5 years shows BridgeBio Pharma's Gross Margin stood at 286.87% in 2021, then crashed by -77bps to 65.4% in 2022, then rose by 1bps to 65.73% in 2023, then dropped by -2bps to 64.57% in 2024, then skyrocketed by 46bps to 94.56% in 2025.
  • Its last three reported values are 94.56% in Q3 2025, 96.7% for Q2 2025, and 97.74% during Q1 2025.